Navigation Links
U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
Date:8/12/2008

CALGARY, Aug. 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI), part of the National Institutes of Health, has started enrolment in a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The trial is being carried out by the Mayo Phase 2 Consortium under the NCI's Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R). The Principal Investigator is Dr. Evanthia Galanis of the Mayo Clinic Cancer Center.

The primary objectives of the study are to assess the antitumour effects of REOLYSIN(R) in patients with metastatic malignant melanoma, as well as the safety profile of REOLYSIN(R). Secondary objectives include assessment of progression free survival and overall survival.

Patients will receive systemic administration of REOLYSIN(R) at a dose of 3x10(10) TCID(50) per day on days 1-5 of each 28 day cycle, and patients may receive up to 12 cycles of treatment. The trial is expected to enroll up to 47 patients with metastatic melanoma.

Approximately 60,000 people are diagnosed with melanoma in the U.S. every year.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. NCI Phase 2 systemic administration clinical trial for patients with metastatic melanoma, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
3. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
4. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
5. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
6. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Provides understanding and access to the ... the worlds leading healthcare companies. Download the ... Global Anemia Partnering Terms and Agreements since 2010 ... and agreements entered into by the world,s leading ... deals - Top deals by value ...
(Date:2/20/2017)... -- This Report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in ... and Liquid & Semi-solid Dosage Forms. The report provides separate comprehensive ... Japan , Europe , Asia-Pacific ... full report: http://www.reportlinker.com/p04707109-summary/view-report.html ... Annual estimates and forecasts are provided for the ...
(Date:2/20/2017)... Feb. 20, 2017 This report analyzes the worldwide ... market is analyzed by the following Segments: Biologic Meshes, and ... US, Canada , Japan ... , and Rest of World. Read the ... forecasts are provided for the period 2015 through 2022. Also, ...
Breaking Medicine Technology:
(Date:2/21/2017)... , ... February 21, 2017 , ... ... Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , The celebration ... tours for community members, clinic employees, the construction team and tribal leadership. ...
(Date:2/21/2017)... ... 21, 2017 , ... Doctors on Liens has announced the addition of ... , to its growing network of doctors in Central and Northern California. Dr. Mendonca ... such as whiplash, back pain, neck pain, hip and knee pain, and headaches. ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas area firm ... County, is embarking on a six month charity event aimed at raising local support ... Cancer is one of the deadliest diseases in America; more than 7.5 million people ...
(Date:2/21/2017)... (PRWEB) , ... February 21, ... ... of technology-enabled clinical trial solutions, today announced the further expansion of its ... applications they can leverage as part of Bioclinica’s extensive and growing eHealth ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is the largest ... demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and Epic. , ... no Health Information Exchange outside of faxing. Medal’s innovative technology “meets providers where ...
Breaking Medicine News(10 mins):